Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094206 · ClinicalTrials.gov registry record · Phase 1
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05094206 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 4 participants.
The verdict
NCT05094206, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
Interventions
- BIOLOGICAL 0.75x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL 1x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL 2.5x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL 5x10^6 cells/kg CAR20.19.22 cells
- BIOLOGICAL Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05094206
The ClinicalTrials.gov registry entry for NCT05094206 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 0.75x10^6 cells/kg CAR20.19.22 cells is the first listed.
NCT05094206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05094206 about?
NCT05094206 is a clinical study titled "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies". In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT05094206?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-06-30. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT05094206?
The interventions under investigation include: 0.75x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), 1x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), 2.5x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), 5x10^6 cells/kg CAR20.19.22 cells (BIOLOGICAL), Dose expansion: The maximum tolerated dose of CAR20.19.22 cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05094206?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.